EAGAN, Minn. — Biothera announced today that it has initiated enrollment of patients in a phase Ib/IIa clinical trial to evaluate the safety and efficacy of Imprime PGG(TM) and Erbitux(R) in patients with metastatic colorectal cancer. Imprime PGG is a unique biological response modifier that enhances specific innate immune cell responses without inducing pro-inflammatory cytokines. Erbitux (cetuximab) is a monoclonal antibody from ImClone Systems that is approved for treatment of colorectal and head and neck cancer. Numerous xenograft mouse models have demonstrated that combining Imprime PGG and Erbitux or other anti-tumor monoclonal antibodies, including Avastin(R) (bevacizumab), and Herceptin(R) (trastuzumab), signi…